1,2-FUSED PYRIMIDINES .7. 3-(DIALKYLAMINO)-1H-PYRIMIDO[1,2-A]QUNOLIN-1-ONES AND DIALKYLAMINO)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONES AS ANTIPLATELET COMPOUNDS
M. Dibraccio et al., 1,2-FUSED PYRIMIDINES .7. 3-(DIALKYLAMINO)-1H-PYRIMIDO[1,2-A]QUNOLIN-1-ONES AND DIALKYLAMINO)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONES AS ANTIPLATELET COMPOUNDS, European journal of medicinal chemistry, 30(1), 1995, pp. 27-38
A number of 3-(dialkylamino)-1H-pyrimido[1,2-a]quinolin-1 ones 3 and 2
-(dialkylamino)-4H-pyrimido [2,1-a]isoquinolin-4-ones 4 were prepared
by treating the corresponding chloro derivatives with an excess of dia
lkylamines. The highest in vitro antiplatelet activity was obtained wh
en the dialkylamino substituent was 1-piperazinyl (compounds 3g and 4e
). The novel 2-(1-piperazinyl)-4H-pyrido[ ,2-a]pyrimidin-4-one 2a was
also prepared by an analogous procedure, which resulted in the most ac
tive compound towards all the platelet aggregation inducers used (ADP,
collagen, A 23187). Moreover, some examples of 1-(dialkylamino)-3H py
rimido[l,2-a]quinolin-3-ones 5 and dialkylamino)-2H-pyrimido[2,1-a]iso
quinolin-2-ones 6 were also obtained (together with negligible or lowe
r amounts of the corresponding isomers 3 and 4, respectively) from the
cyclocondensation of the appropriate ethyl N,N-dialkylmalonamate/phos
phorus oxychloride reagents 13 with 2-aminoquinoline or 1-aminoisoquin
oline. These;latter compounds showed a rather low antiplatelet activit
y.